Tzipi Ozer-Armon

Lumenis sells Surgical Business to Boston Scientific (NYSE: BSX) for $1.07 billion

Lumenis sells Surgical Business to Boston Scientific (NYSE: BSX) for $1.07 billion

Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at $1.07 bln, subject to closing adjustments. The Surgical Business includes laser and fibers solutions for minimally-invasive surgical procedures in Urology and ENT.

Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.